Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Int J Cancer. 2018 Nov 1;143(9):2126-2132. doi: 10.1002/ijc.31551. Epub 2018 May 10.
Breast cancer accounts for more than one million new cases annually and is the leading cause of death in women globally. HER2 overexpression induces cellular and humoral immune responses against the HER2 protein and is associated with higher tumor proliferation rates. Trastuzumab-based therapies are effectively and widely used as standard of care in HER2-amplified/overexpressed breast cancer patients; one cited mechanism of action is the induction of passive immunity and antibody-dependent cellular cytotoxicity against malignant breast cancer cells. These findings drove the efforts to generate antigen-specific immunotherapy to trigger the patient's immune system to target HER2-overexpressing tumor cells, which led to the development of various vaccines against the HER2 antigen. This article discusses the various anti-HER2 vaccine formulations and strategies and their potential role in the metastatic and adjuvant settings.
乳腺癌每年新发病例超过 100 万，是全球女性死亡的主要原因。HER2 过表达诱导针对 HER2 蛋白的细胞和体液免疫反应，并与更高的肿瘤增殖率相关。曲妥珠单抗为基础的治疗方案被广泛有效地用作 HER2 扩增/过表达乳腺癌患者的标准治疗方法；一个被引用的作用机制是诱导针对恶性乳腺癌细胞的被动免疫和抗体依赖性细胞细胞毒性。这些发现促使人们努力开发针对 HER2 过表达肿瘤细胞的抗原特异性免疫疗法，从而开发了针对 HER2 抗原的各种疫苗。本文讨论了各种抗 HER2 疫苗制剂和策略及其在转移性和辅助性环境中的潜在作用。
